Company Governance and Structure - In January 2026, the company announced an employee stock ownership plan draft, aiming to implement equity incentives for no more than 145 employees, with performance targets set for 2026 to 2028. The revenue target for 2026 is set at 1 billion yuan, and the profit target is set at 300 million yuan [2]. Product Development Progress - The company expects significant advancements in multiple generic and innovative drugs in 2026. The local production registration for Compound Sodium Sulfate Tablets (first generic in China) and Hewei Zhengchang Pills (exclusive in China) is anticipated to be approved in the first half of 2026. The eye drop medication for presbyopia, Hyoscyamine Sulfate Eye Drops (first generic in China), is expected to be approved in the second half of 2026. Additionally, the innovative drug CKBA Cream for pediatric vitiligo is planned to initiate its Phase II clinical trial with the first patient enrollment in the first quarter of 2026, alongside a submission to the FDA [3]. Recent Stock Performance - On December 15, 2025, the company was included in the sample range of the CSI 1000 Index, with market expectations that it may be included in related ETFs, potentially impacting stock liquidity in the long term. On February 2, 2026, the company's controlling shareholders pledged part of their shares, totaling 13.81% of the company's total equity, citing personal funding needs. On February 13, 2026, the company's stock price increased by 2.05%, reaching a total market value of 13.969 billion yuan, with a net inflow of 1.8773 million yuan from major funds, reflecting short-term market interest [4].

Core Viewpoint - The company, 泰恩康 (301263.SZ), is experiencing stable revenue from existing products while anticipating significant growth from upcoming core products expected to be approved or submitted for approval in the near future [1] Existing Products - The company’s current products, including the dual-purpose health medication "爱廷玖", ophthalmic drug "沃丽汀", and traditional Chinese medicine, are maintaining stable revenue [1] Upcoming Product Approvals - Multiple core products are expected to be approved or submitted for approval: - "爱廷列" Finasteride and Tadalafil compound capsule (first domestic generic) is expected to be approved by December 2025 - Lidocaine and Prilocaine aerosol (first domestic generic) has completed clinical trials, with registration expected to be accepted by the drug regulatory authority soon - Compound Sodium Sulfate tablets (first domestic generic) are anticipated to be approved in the first half of 2026 - "和胃整肠丸" (exclusive domestic) localization production registration is expected to be approved in the first half of 2026 - Pilocarpine eye drops for presbyopia (first domestic generic) are expected to be approved in the second half of 2026 [1] Revenue Growth Projections - With the approval and launch of the aforementioned core products, the company expects a significant increase in revenue from existing business segments in 2026, with explosive growth anticipated in 2027 and 2028 [1]

1. Reported Industry Investment Rating - No information provided in the given content 2. Core Viewpoints of the Report - The company's 2026 Employee Stock Ownership Plan (Draft) shows management's confidence in future development and the core team's optimism about the market prospects of core business products [26]. - The company has set three - year (2026 - 2028) performance assessment targets for the employee stock ownership plan, aiming to achieve revenue of 1 billion yuan in 2026, 1.5 billion yuan in 2027, and 2 billion yuan in 2028, and考核利润 of 300 million yuan in 2026, 500 million yuan in 2027, and 800 million yuan in 2028 [26]. - With the approval of multiple core products, the company's existing business revenue is expected to grow significantly in 2026, and there will be explosive growth in 2027 and 2028 [28]. 3. Summary by Relevant Catalogs 3.1 Research Basic Situation - Research object: Taienkang [16] - Industry: Pharmaceutical commerce [16] - Reception time: January 29, 2026 [16] - Listed company reception personnel: Li Ting, Director, Deputy General Manager, and Secretary of the Board of Directors [16] 3.2 Detailed Research Institutions - Securities companies: Huatai Securities, China Merchants Securities, Ping An Securities, Zhongtai Securities, Founder Securities, Huachuang Securities, Cinda Securities, CITIC Securities Co., Ltd., Tianfeng Securities, Shenwan Hongyuan, Guotai Haitong, Industrial Securities, Guohai Securities, Huafu Securities, Huaxi Securities, Galaxy Securities [17][18][20] - Fund management companies: Dacheng, Huabao, Huian, Huatai - PineBridge Fund, China Asset Management, Galaxy, Jianxin, Hangzhou Youyizeng Private Equity, Puyin AXA, Anxin, Hehe (Beijing) Private Equity, Morgan Stanley Fund Management (China), Hainan Ling Private Equity, Guoshou Anbao [17][18][19] - Asset management companies: Yong'an Guofu, Shanghai Yuxiu, Guangdong Hongyi, Huafu Securities, Zhongyin International Securities Co., Ltd. Asset Management, Ping An Insurance Asset Management, Fushun Asset Management (Shanghai), Zhonghuili Asset Management, Shanghai Qingding, Beijing Hanhe and Hanhua [18][19][20] - Investment companies: Shanghai Hengfu, Shanghai Zige, Zhejiang Yiheng, Beijing Zhuoyu, Shanghai Guanche [18][19] - Others: Western Medicine, Dongfang Investment Consulting, Dongcai Medicine, Hwa Site Asset Management, Northeast Medicine, Dongfang Medicine, Xiangwang Fund [18][19][20] 3.3 Research Institution Proportion - No information provided in the given content 3.4 Main Content Data - **Employee Stock Ownership Plan** - Fund - raising: The total amount of funds to be raised is 33.608 million yuan, with no more than 145 participants including directors, senior managers, and core employees, and all funds come from employees' legal salaries and self - raised funds [26]. - Assessment targets: From 2026 - 2028, the assessment indicators are revenue and考核利润 (deducted non - recurring profit and loss attributable to the parent + R & D expenses - investment income from associated and joint - venture enterprises - share - based payment expenses) [26]. - Incentive form: Employee stock ownership plan, employees need to contribute funds first and obtain shares through non - trading transfer [26]. - Unlock ratio: Unlock in three phases from 2026 - 2028, with 40%, 40%, and 20% respectively [28]. - Incentive shares: Approximately 1.98 million shares, sourced from the company's previous share repurchases [28]. - **Revenue and Profit Targets** - The company's existing products such as "Aitingjiu" for sexual health, "Wolitin" for ophthalmology, and Chinese patent medicines will maintain stable income [28]. - Multiple core products will be approved or applied for, including "Aitinglie" non - finasteride - tadalafil compound capsule (domestic first imitation) approved in December 2025, lidocaine - prilocaine aerosol (domestic first imitation) expected to be accepted by the drug administration soon, compound sodium sulfate tablets (domestic first imitation) expected to be approved in the first half of 2026, Heweizhengchang Pills (domestic exclusive) for localized production registration expected to be approved in the first half of 2026, and pilocarpine hydrochloride eye drops for presbyopia (domestic first imitation) expected to be approved in the second half of 2026 [28]. - **Heweizhengchang Pills Localized Production** - Since the second half of 2025, the company has carried out brand promotion in traditional advantageous regions such as Guangdong, Guangxi, and Fujian through platforms like Focus Media, Xiaohongshu, and Douyin [28]. - Actively expand third - party terminal channels such as clinics and Internet hospitals, and increase investment in online platforms such as Douyin, JD, and Tmall. Sales on the Douyin platform have increased significantly in January [28]. - After the domestic localization of Heweizhengchang Pills, multiple product specifications will be added to meet different needs and maintain the price system, with good sales expected in the first and second quarters of this year [28]. - **CKBA for Alzheimer's Disease** - Developed from AKBA, a natural triterpenoid compound from frankincense, CKBA can specifically target MFE - 2, a key metabolic enzyme in the peroxisomal β - oxidation pathway, maintaining lipid metabolism homeostasis in microglia and inhibiting the release of pro - inflammatory factors [28][29]. - Animal experiments show that oral CKBA can cross the blood - brain barrier, has no obvious toxic side effects, and has multiple therapeutic effects in Alzheimer's disease model mice [29]. - **Commercialization Preparation for New Products** - Increase brand promotion investment, cooperate with Meituan in addition to existing channels, and the sales on online platforms such as Meituan, Tmall, JD, and Douyin are increasing [29]. - Establish a specialized third - party terminal team to develop clinic and Internet hospital channels and adjust the sales team [29]. - For specific products, promote the inclusion of compound sodium sulfate tablets in medical insurance after approval; start medical insurance - related work for non - finasteride - tadalafil compound capsules, and continue in - depth brand promotion [30]. - **Progress of Child Vitiligo and Rosacea** - Rosacea may progress faster and is expected to be the first indication for CKBA to submit a registration application. The company aims to complete Phase III clinical trials by the end of 2027 [30]. - Child vitiligo Phase II clinical trials aim to enroll the first patient in March - April 2026 and basically complete Phase II clinical trials in the first half of 2027 [31]. - **Overseas Market of Child Vitiligo** - The company focuses on the domestic registration and listing of child vitiligo in 2 - 12 - year - old children. There is currently no approved product globally, and the company plans to start the IND application for the US FDA this year [32].

Summary of the Conference Call for Guangdong Tianen Pharmaceutical Co., Ltd. Company Overview - Guangdong Tianen Pharmaceutical Co., Ltd. specializes in the research, production, and sales of pharmaceuticals, with key products including Hewei Zhengchang Wan, "Woliting" Lecithin Iodine Tablets, and "Aiting Jiu" Dapoxetine Hydrochloride Tablets. The company was established in 1999 and has developed a significant sales network over 20 years [3][3][3]. Key Points Discussed Employee Stock Ownership Plan - The company disclosed a draft for the 2026 Employee Stock Ownership Plan, aiming to raise a total of 33.608 million yuan, involving up to 145 participants including directors and core employees. The plan reflects management's confidence in future growth and the market potential of core business products [12][12][12]. Performance Targets - The performance assessment period for the employee stock plan is set from 2026 to 2028, with specific targets: - Revenue: 1 billion yuan in 2026, 1.5 billion yuan in 2027, and 2 billion yuan in 2028 - Profit: 300 million yuan in 2026, 500 million yuan in 2027, and 800 million yuan in 2028 [15][15][15]. Product Development and Approval - The company expects multiple core products to be approved or submitted for approval, including: - "Aiting Lie" Finasteride and Tadalafil Compound Capsules (first domestic generic) approved in December 2025 - Lidocaine and Prilocaine Aerosol (first domestic generic) nearing regulatory submission - Compound Sodium Sulfate Tablets (first domestic generic) expected approval in H1 2026 - Localization of Hewei Zhengchang Wan production expected to be approved in H1 2026 - Pilocarpine Eye Drops for presbyopia (first domestic generic) anticipated approval in H2 2026 [18][19][19]. Marketing and Sales Strategy - The company has initiated brand promotion efforts in key regions and expanded online sales through platforms like Douyin and JD.com. The localized production of Hewei Zhengchang Wan is expected to enhance sales, with good performance anticipated in Q1 and Q2 of the current year [20][20][20]. Alzheimer's Disease Research - The company is developing CKBA for Alzheimer's disease, focusing on a compound derived from traditional Chinese medicine. CKBA has shown promising results in animal models, demonstrating cognitive improvement and neuroprotection [21][22][22]. Future Product Launches - The company plans to enhance brand promotion and has established a dedicated team for third-party channels, including clinics and internet hospitals. The approval of Compound Sodium Sulfate Tablets will be followed by efforts to include it in medical insurance [23][24][24]. Clinical Trials for Skin Conditions - The company is prioritizing the registration of treatments for pediatric vitiligo and rosacea, with rosacea expected to progress faster due to its shorter treatment cycle. The market potential for rosacea is significant, with over 50 million patients in China [25][26][27]. International Market Exploration - The company aims to explore overseas markets for CKBA, particularly in the pediatric vitiligo segment, where there are currently no approved treatments. Plans to initiate IND applications with the FDA are underway [27][27][27]. Additional Notes - The conference highlighted the company's commitment to innovation and growth in the pharmaceutical sector, with a focus on integrating research, production, and sales [3][3][3]. - The management emphasized the importance of maintaining a robust pipeline of products and adapting to market needs through strategic marketing and sales initiatives [20][20][20].

Group 1: Investor Relations Activity - The investor relations activity involved specific targeted research with participation from various fund management companies and securities firms [2][3]. - The meeting was held online on a Thursday morning, with a duration of 50 minutes [2]. Group 2: Employee Stock Ownership Plan - The company disclosed a draft for an employee stock ownership plan aiming to raise a total of CNY 33.608 million, involving directors, senior management, and core employees [3]. - The performance assessment period for the plan is set from 2026 to 2028, with specific revenue and profit targets: - Revenue targets: CNY 1 billion in 2026, CNY 1.5 billion in 2027, and CNY 2 billion in 2028 - Profit targets: CNY 300 million in 2026, CNY 500 million in 2027, and CNY 800 million in 2028 [3][4]. Group 3: Product Development and Market Strategy - The company has several core products expected to be approved or submitted for approval, including "Aitinglie" and "Lidocaine" aerosol, with anticipated revenue growth from existing products and new approvals [4][5]. - The company is actively promoting the "Hewei Zhengchang Wan" product through various media channels and expanding its sales through clinics and online platforms [5][8]. - The company plans to enhance brand promotion and has established a dedicated team for third-party channels, focusing on clinics and internet hospitals [8]. Group 4: Alzheimer's Disease Research - The company is developing CKBA for Alzheimer's disease, which has shown promising results in animal models, including cognitive improvement and reduced neuroinflammation [6][7]. - CKBA's mechanism targets MFE-2, a key enzyme in lipid metabolism, which is crucial for maintaining the homeostasis of microglial cells [7]. Group 5: Clinical Trials and Market Potential - The company is prioritizing the registration of treatments for pediatric vitiligo and rosacea, with rosacea expected to progress faster due to a shorter treatment cycle [9][10]. - The domestic market for pediatric vitiligo is significant, with no existing treatments approved by the FDA, indicating potential for market expansion [11]. Group 6: Forward-Looking Statements - The report includes forward-looking statements regarding future plans and performance forecasts, emphasizing the need for investors to recognize associated risks [11].

Group 1 - The company expects a net profit attributable to shareholders for the fiscal year 2025 to be between 25 million to 35 million yuan, representing a year-on-year decline of 67.66% to 76.90% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 27 million to 37 million yuan, reflecting a year-on-year decrease of 65.11% to 74.54% [1] - The decline in performance is primarily attributed to intense market competition in the core sector of sexual health and a decrease in sales revenue [1] Group 2 - The core product "He Wei Zheng Chang Wan" is affected by insufficient production capacity and delays in imports [1] - Increased investment in research and development and brand promotion has led to a rise in selling expenses, thereby compressing profit margins [1]

Core Viewpoint - The company has announced an employee stock ownership plan (ESOP) for 2026, aiming to incentivize up to 145 individuals, including directors and key employees, with a total funding cap of 33.608 million yuan [1] Group 1: Employee Stock Ownership Plan - The ESOP will be funded through employees' legal salaries and self-raised funds, with no financial assistance or loan guarantees provided by the company [1] - The repurchase price for the shares is set at 16.93 yuan per share, with a maximum of 1.9851 million shares to be held, representing approximately 0.47% of the total share capital [1] - Performance targets for the years 2026 to 2028 have been established, with revenue and profit goals progressively increasing each year [1] Group 2: Performance Assessment and Goals - For 2026, the revenue target is set at 1 billion yuan, with a trigger value of 900 million yuan; the profit target is 300 million yuan, with a trigger value of 270 million yuan [1] - The revenue target for 2027 increases to 1.5 billion yuan (trigger value: 1.35 billion yuan), and the profit target rises to 500 million yuan (trigger value: 450 million yuan) [1] - By 2028, the revenue target reaches 2 billion yuan (trigger value: 1.8 billion yuan), and the profit target is set at 800 million yuan (trigger value: 720 million yuan) [1] Group 3: Unlocking Rules and Strategic Goals - If either revenue or profit meets the target, the unlocking ratio is 100%; if both meet the trigger values but not the targets, the unlocking ratio is 90% [2] - The ESOP aims to establish a profit-sharing mechanism between employees and the company, enhancing team stability and competitiveness to support long-term strategic goals [2] Group 4: Product Pipeline and Market Position - The company has received approval for a Phase II clinical trial of its core product, CKBA cream, targeting pediatric vitiligo, with patient enrollment expected to start in Q1 2026 [2] - The company anticipates approvals for its generic drugs, including compound sodium sulfate tablets and a unique gastrointestinal product, in the first half of 2026, with another eye medication expected in the second half [2] - The company forecasts continued growth in its sexual health segment, driven by brand promotion and the launch of new products [3]

Group 1 - The core point of the news is that Guangdong Taiankang Pharmaceutical Co., Ltd. has disclosed its employee stock ownership plan for 2026, aiming to raise a maximum of 33.608 million yuan, with participation from up to 145 individuals including directors, senior management, and key employees [1] - The employee stock ownership plan is closely tied to the company's performance over the next three years, with assessment indicators including both "operating revenue" and "assessed profit," targeting significant growth [1][2] - The plan outlines specific unlock periods and performance targets, with the first unlock period set for 2026, requiring operating revenue to reach 1 billion yuan and assessed profit to hit 270 million yuan [2] Group 2 - The company is expected to see significant revenue growth as several core products are set to be approved or submitted for approval, including a domestic first generic of lidocaine and prilocaine aerosol, which is anticipated to complete registration by 2026 [2][3] - Participants in the employee stock ownership plan are required to use their own funds for subscription, with shares sourced from the company's repurchased stock at a price of 16.93 yuan per share [3] - The company believes that this long-term mechanism of employee stock ownership will effectively motivate the core team's enthusiasm and creativity, promoting the research, market promotion, and sales of core products to ensure the achievement of high growth targets [3]

Core Viewpoint - The company, TianKang (301263.SZ), forecasts a significant decline in net profit for the fiscal year 2025, with expected figures between 25 million to 35 million yuan, representing a year-on-year decrease of 67.66% to 76.90% [1] Group 1: Financial Performance - The net profit attributable to shareholders is projected to be between 25 million to 35 million yuan, a decrease of 67.66% to 76.90% year-on-year [1] - The net profit after deducting non-recurring gains and losses is expected to be between 27 million to 37 million yuan, reflecting a year-on-year decline of 65.11% to 74.54% [1] Group 2: Business Segments - The company's core business in sexual health has experienced a decline in sales revenue due to increased competition and the number of competing products, although there are signs of a gradual market recovery [1] - The product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) has a strong brand moat, and the company plans to enhance brand promotion efforts to boost sales [1] - The launch of the new product "Aiting Lie" (Finasteride and Tadalafil Capsules) is expected to contribute to growth in the sexual health segment moving forward [1] Group 3: Product Challenges - The core product "He Wei Zheng Chang Wan" (Stomach and Intestine Regulating Pills) has seen a decline in sales due to production capacity issues at the Thai manufacturer and delays in imports [1] - The company is actively working on the registration and approval process for "He Wei Zheng Chang Wan" in China, aiming to resolve production capacity bottlenecks [1]

Core Viewpoint - The company Tainkang (301263) forecasts a significant decline in net profit for 2025, estimating a range of 25 million to 35 million yuan, representing a decrease of 67.66% to 76.9% compared to the previous year [2] Group 1: Business Performance - The core business segment of sexual health has experienced a decline in sales revenue due to increased competition and the number of competing products [2] - Despite the challenges, there is a noted trend of gradual market demand recovery [2] - The product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) has a strong brand moat, and the company plans to enhance brand promotion to boost sales [2] Group 2: Product Development and Challenges - The core product "He Wei Zheng Chang Wan" faced a decline in sales due to insufficient production capacity from the Thai manufacturer and delays in imports [2] - The company is actively working on the registration and approval process for "He Wei Zheng Chang Wan" in China to resolve production capacity bottlenecks [2] - The launch of the new product "Aiting Lie" (Finasteride and Tadalafil Capsules) is expected to contribute to growth in the sexual health segment [2] Group 3: Financial Outlook - The company plans to increase investment in research and development while also boosting brand promotion efforts, which will lead to higher sales expenses and compress profit margins [2]